BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

456 related articles for article (PubMed ID: 23219535)

  • 1. Frequency-modulated pulses of ERK activity transmit quantitative proliferation signals.
    Albeck JG; Mills GB; Brugge JS
    Mol Cell; 2013 Jan; 49(2):249-61. PubMed ID: 23219535
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential effect of growth factors on invasion and proliferation of endocrine resistant breast cancer cells.
    Khajah MA; Al Saleh S; Mathew PM; Luqmani YA
    PLoS One; 2012; 7(7):e41847. PubMed ID: 22860018
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structure of the EGF receptor transactivation circuit integrates multiple signals with cell context.
    Joslin EJ; Shankaran H; Opresko LK; Bollinger N; Lauffenburger DA; Wiley HS
    Mol Biosyst; 2010 Jul; 6(7):1293-306. PubMed ID: 20458382
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of Runx2 in crosstalk between Mek/Erk and PI3K/Akt signaling in MCF-10A cells.
    Tandon M; Chen Z; Pratap J
    J Cell Biochem; 2014 Dec; 115(12):2208-17. PubMed ID: 25147082
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Blocking the PI3K/AKT and MEK/ERK signaling pathways can overcome gefitinib-resistance in non-small cell lung cancer cell lines.
    Li H; Schmid-Bindert G; Wang D; Zhao Y; Yang X; Su B; Zhou C
    Adv Med Sci; 2011; 56(2):275-84. PubMed ID: 22037177
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Receptor Level Mechanisms Are Required for Epidermal Growth Factor (EGF)-stimulated Extracellular Signal-regulated Kinase (ERK) Activity Pulses.
    Sparta B; Pargett M; Minguet M; Distor K; Bell G; Albeck JG
    J Biol Chem; 2015 Oct; 290(41):24784-92. PubMed ID: 26304118
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impaired SHP2-mediated extracellular signal-regulated kinase activation contributes to gefitinib sensitivity of lung cancer cells with epidermal growth factor receptor-activating mutations.
    Lazzara MJ; Lane K; Chan R; Jasper PJ; Yaffe MB; Sorger PK; Jacks T; Neel BG; Lauffenburger DA
    Cancer Res; 2010 May; 70(9):3843-50. PubMed ID: 20406974
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PIK3CA mutation uncouples tumor growth and cyclin D1 regulation from MEK/ERK and mutant KRAS signaling.
    Halilovic E; She QB; Ye Q; Pagliarini R; Sellers WR; Solit DB; Rosen N
    Cancer Res; 2010 Sep; 70(17):6804-14. PubMed ID: 20699365
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Insights into erlotinib action in pancreatic cancer cells using a combined experimental and mathematical approach.
    Lange F; Rateitschak K; Kossow C; Wolkenhauer O; Jaster R
    World J Gastroenterol; 2012 Nov; 18(43):6226-34. PubMed ID: 23180942
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mig-6 overcomes gefitinib resistance by inhibiting EGFR/ERK pathway in non-small cell lung cancer cell lines.
    Li ZX; Qu LY; Wen H; Zhong HS; Xu K; Qiu XS; Wang EH
    Int J Clin Exp Pathol; 2014; 7(10):7304-11. PubMed ID: 25400829
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sensitivity to gefitinib (Iressa, ZD1839) in non-small cell lung cancer cell lines correlates with dependence on the epidermal growth factor (EGF) receptor/extracellular signal-regulated kinase 1/2 and EGF receptor/Akt pathway for proliferation.
    Ono M; Hirata A; Kometani T; Miyagawa M; Ueda S; Kinoshita H; Fujii T; Kuwano M
    Mol Cancer Ther; 2004 Apr; 3(4):465-72. PubMed ID: 15078990
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner.
    Joseph EW; Pratilas CA; Poulikakos PI; Tadi M; Wang W; Taylor BS; Halilovic E; Persaud Y; Xing F; Viale A; Tsai J; Chapman PB; Bollag G; Solit DB; Rosen N
    Proc Natl Acad Sci U S A; 2010 Aug; 107(33):14903-8. PubMed ID: 20668238
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stochastic ERK activation induced by noise and cell-to-cell propagation regulates cell density-dependent proliferation.
    Aoki K; Kumagai Y; Sakurai A; Komatsu N; Fujita Y; Shionyu C; Matsuda M
    Mol Cell; 2013 Nov; 52(4):529-40. PubMed ID: 24140422
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of glioblastoma dispersal by the MEK inhibitor PD0325901.
    Shannon S; Jia D; Entersz I; Beelen P; Yu M; Carcione C; Carcione J; Mahtabfar A; Vaca C; Weaver M; Shreiber D; Zahn JD; Liu L; Lin H; Foty RA
    BMC Cancer; 2017 Feb; 17(1):121. PubMed ID: 28187762
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Switching from MAPK-dependent to MAPK-independent repression of the sodium-iodide symporter in 2D and 3D cultured normal thyroid cells.
    Ingeson-Carlsson C; Nilsson M
    Mol Cell Endocrinol; 2013 Dec; 381(1-2):241-54. PubMed ID: 23969277
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epidermal growth factor stimulates RSK2 activation through activation of the MEK/ERK pathway and src-dependent tyrosine phosphorylation of RSK2 at Tyr-529.
    Kang S; Dong S; Guo A; Ruan H; Lonial S; Khoury HJ; Gu TL; Chen J
    J Biol Chem; 2008 Feb; 283(8):4652-7. PubMed ID: 18156174
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Platelet-activating factor induces ovine fetal pulmonary venous smooth muscle cell proliferation: role of epidermal growth factor receptor transactivation.
    Zhou W; Ibe BO; Raj JU
    Am J Physiol Heart Circ Physiol; 2007 Jun; 292(6):H2773-81. PubMed ID: 17322418
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synergistic inhibition of ovarian cancer cell growth by combining selective PI3K/mTOR and RAS/ERK pathway inhibitors.
    Sheppard KE; Cullinane C; Hannan KM; Wall M; Chan J; Barber F; Foo J; Cameron D; Neilsen A; Ng P; Ellul J; Kleinschmidt M; Kinross KM; Bowtell DD; Christensen JG; Hicks RJ; Johnstone RW; McArthur GA; Hannan RD; Phillips WA; Pearson RB
    Eur J Cancer; 2013 Dec; 49(18):3936-44. PubMed ID: 24011934
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Axin inhibits extracellular signal-regulated kinase pathway by Ras degradation via beta-catenin.
    Jeon SH; Yoon JY; Park YN; Jeong WJ; Kim S; Jho EH; Surh YJ; Choi KY
    J Biol Chem; 2007 May; 282(19):14482-92. PubMed ID: 17374607
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The synergistic effect of EGFR tyrosine kinase inhibitor gefitinib in combination with aromatase inhibitor anastrozole in non-small cell lung cancer cell lines.
    Shen L; Li Z; Shen S; Niu X; Yu Y; Li Z; Liao M; Chen Z; Lu S
    Lung Cancer; 2012 Dec; 78(3):193-200. PubMed ID: 22985911
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.